{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:21:34Z","timestamp":1794500494969,"version":"4.9.1"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Biol Endocrinol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ovarian hyperstimulation syndrome (OHSS) is a potentially life-threating iatrogenic complication of the early luteal phase and\/or early pregnancy after in vitro fertilization (IVF) treatment. The aim of the current study was to identify the most effective methods for preventing of and reducing the incidence and severity of OHSS in IVF patients. A systematic review of systematic reviews of randomized controlled trials (RCTs) with meta-analysis was used to assess each potential intervention (PROSPERO website, CRD 268626) and only studies with the highest quality were included in the qualitative analysis. Primary outcomes included prevention and reduction of OHSS incidence and severity. Secondary outcomes were maternal death, incidence of hospital admission, days of hospitalization, and reproductive outcomes, such as incidence of live-births, clinical pregnancies, pregnancy rate, ongoing pregnancy, miscarriages, and oocytes retrieved. A total of specific interventions related to OHSS were analyzed in 28 systematic reviews of RCTs with meta-analyses. The quality assessment of the included studies was high, moderate, and low for 23, 2, and 3 studies, respectively. The certainty of evidence (CoE) for interventions was reported for 37 specific situations\/populations and resulted high, moderate, and low-to-very low for one, 5, and 26 cases, respectively, while it was not reported in 5 cases. Considering the effective interventions without deleterious reproductive effects, GnRH-ant co-treatment (36 RCTs; OR 0.61, 95% C 0.51 to 0.72,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20097,944; I\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u200931%) and GnRH agonist triggering (8 RCTs; OR 0.15, 95% CI 0.05 to 0.47,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009989; I\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u200942%) emerged as the most effective interventions for preventing OHSS with a moderate CoE, even though elective embryo cryopreservation exhibited a low CoE. Furthermore, the use of mild ovarian stimulation (9 RCTs; RR 0.26, CI 0.14 to 0.49,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091,925; I\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u20090%), and dopaminergic agonists (10 RCTs; OR 0.32, 95% CI 0.23 to 0.44,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091,202; I\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u200913%) coadministration proved effective and safe with a moderate CoE. In conclusion, the current study demonstrates\u00a0that only a few interventions currently can be considered effective to reduce the incidence of OHSS and its severity with high\/moderate CoE despite the numerous published studies on the topic. Further well-designed RCTs are needed, particularly for GnRH-a down-regulated IVF cycles.\n                  <\/jats:p>","DOI":"10.1186\/s12958-023-01113-6","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T07:02:06Z","timestamp":1689922926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Interventions to prevent or reduce the incidence and severity of ovarian hyperstimulation syndrome: a systematic umbrella review of the best clinical evidence"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2767-8295","authenticated-orcid":false,"given":"Stefano","family":"Palomba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Costanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9099-3047","authenticated-orcid":false,"given":"Scott M.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Caserta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6884-5366","authenticated-orcid":false,"given":"Peter","family":"Humaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"1113_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0015-0282(16)36123-4","volume":"17","author":"ML Taymor","year":"1966","unstructured":"Taymor ML, Sturgis SH. Induction of ovulation with human postmenopausal gonadotropin. II. Probable causes of overstimulation. Fertil Steril. 1966;17:736\u201341.","journal-title":"Fertil Steril"},{"key":"1113_CR2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.rbmo.2020.06.004","volume":"41","author":"K Rotshenker-Olshinka","year":"2020","unstructured":"Rotshenker-Olshinka K, Badeghiesh A, Volodarsky-Perel A, Steiner N, Suarthana E, Dahan MH. Trends in ovarian hyperstimulation syndrome hospitalization rates in the USA: an ongoing concern. Reprod Biomed Online. 2020;41:357\u201360.","journal-title":"Reprod Biomed Online"},{"key":"1113_CR3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.fertnstert.2020.04.004","volume":"114","author":"DA Schirmer 3rd","year":"2020","unstructured":"Schirmer DA 3rd, Kulkarni AD, Zhang Y, Kawwass JF, Boulet SL, Kissin DM. Ovarian hyperstimulation syndrome after assisted reproductive technologies: trends, predictors, and pregnancy outcomes. Fertil Steril. 2020;114:567\u201378.","journal-title":"Fertil Steril"},{"key":"1113_CR4","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1093\/humrep\/dew149","volume":"31","author":"P Humaidan","year":"2016","unstructured":"Humaidan P, Nelson SM, Devroey P, Coddington CC, Schwartz LB, Gordon K, Frattarelli JL, Tarlatzis BC, Fatemi HM, Lutjen P, et al. Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. Hum Reprod. 2016;31:1997\u20132004.","journal-title":"Hum Reprod"},{"key":"1113_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3109\/09513590.2015.1037268","volume":"31","author":"AK Dey","year":"2015","unstructured":"Dey AK, Dubey A, Mittal K, Kale S. Spontaneous ovarian hyperstimulation syndrome - understanding the dilemma. Gynecol Endocrinol. 2015;31:587\u20139.","journal-title":"Gynecol Endocrinol"},{"key":"1113_CR6","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.fertnstert.2009.07.1662","volume":"94","author":"LC Grossman","year":"2010","unstructured":"Grossman LC, Michalakis KG, Browne H, Payson MD, Segars JH. The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome. Fertil Steril. 2010;94:1392\u20138.","journal-title":"Fertil Steril"},{"key":"1113_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/uog.14684","volume":"45","author":"CO Nastri","year":"2015","unstructured":"Nastri CO, Teixeira DM, Moroni RM, Leit\u00e3o VM, Martins WP. Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention. Ultrasound Obstet Gynecol. 2015;45:377\u201393.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"1113_CR8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/GCO.0000000000000284","volume":"28","author":"M Kwik","year":"2016","unstructured":"Kwik M, Maxwell E. Pathophysiology, treatment and prevention of ovarian hyperstimulation syndrome. Curr Opin Obstet Gynecol. 2016;28:236\u201341.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"1113_CR9","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.ajem.2019.05.018","volume":"37","author":"D Timmons","year":"2019","unstructured":"Timmons D, Montrief T, Koyfman A, Long B. Ovarian hyperstimulation syndrome: a review for emergency clinicians. Am J Emerg Med. 2019;37:1577\u201384.","journal-title":"Am J Emerg Med"},{"key":"1113_CR10","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1055\/s-0030-1265670","volume":"28","author":"R G\u00f3mez","year":"2010","unstructured":"G\u00f3mez R, Soares SR, Busso C, Garcia-Velasco JA, Sim\u00f3n C, Pellicer A. Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med. 2010;28:448\u201357.","journal-title":"Semin Reprod Med"},{"key":"1113_CR11","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/1933719116672588","volume":"23","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, \u00c1vila J, Naftolin F. The ovarian renin-angiotensin system (OVRAS): a major factor in ovarian function and disease. Reprod Sci. 2016;23:1644\u201355.","journal-title":"Reprod Sci"},{"key":"1113_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10815-018-1372-5","volume":"36","author":"K Stouffs","year":"2019","unstructured":"Stouffs K, Daelemans S, Santos-Ribeiro S, Seneca S, Gheldof A, G\u00fcrb\u00fcz AS, De Vos M, Tournaye H, Blockeel C. Rare genetic variants potentially involved in ovarian hyperstimulation syndrome. J Assist Reprod Genet. 2019;36:491\u20137.","journal-title":"J Assist Reprod Genet"},{"key":"1113_CR13","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.fertnstert.2016.08.048","volume":"106","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2016","unstructured":"Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016;106:1634\u201347.","journal-title":"Fertil Steril"},{"key":"1113_CR14","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1093\/humrep\/deq080","volume":"25","author":"DD Braat","year":"2010","unstructured":"Braat DD, Schutte JM, Bernardus RE, Mooij TM, van Leeuwen FE. Maternal death related to IVF in the Netherlands 1984\u20132008. Hum Reprod. 2010;25:1782\u20136.","journal-title":"Hum Reprod"},{"key":"1113_CR15","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0015-0282(00)00492-1","volume":"73","author":"RS Mathur","year":"2000","unstructured":"Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:901\u20137.","journal-title":"Fertil Steril"},{"key":"1113_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S1472-6483(10)60042-9","volume":"19","author":"A Golan","year":"2009","unstructured":"Golan A, Weissman A. Symposium: update on prediction and management of OHSS. A modern classification of OHSS. Reprod Biomed Online. 2009;19:28\u201332.","journal-title":"Reprod Biomed Online"},{"key":"1113_CR17","doi-asserted-by":"publisher","first-page":"hoaa009","DOI":"10.1093\/hropen\/hoaa009","volume":"2020","author":"E Bosch","year":"2020","unstructured":"TEGGOOvarian Stimulation, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, Kolibianakis E, Kunicki M, La Marca A, Lainas G, Le Clef N, et al. ESHRE guideline: ovarian stimulation for IVF\/ICSI. Hum Reprod Open. 2020;2020:hoaa009.","journal-title":"Hum Reprod Open"},{"key":"1113_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000524904","volume":"87","author":"GG Iorio","year":"2022","unstructured":"Iorio GG, Carbone L, Conforti A, Rovetto MY, Picarelli S, Cariati F, Strina I, Papanikolaou E, Alviggi C. Ovarian hyperstimulation syndrome after GnRH agonist triggering and freeze-all protocol? Never not, hardly ever: a systematic review of case reports. Gynecol Obstet Invest. 2022;87:259\u201365.","journal-title":"Gynecol Obstet Invest"},{"key":"1113_CR19","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/09513590.2019.1650345","volume":"35","author":"B Lunenfeld","year":"2019","unstructured":"Lunenfeld B, Bilger W, Longobardi S, Kirsten J, D\u2019Hooghe T, Sunkara SK. Decision points for individualized hormonal stimulation with recombinant gonadotropins for treatment of women with infertility. Gynecol Endocrinol. 2019;35:1027\u201336.","journal-title":"Gynecol Endocrinol"},{"key":"1113_CR20","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.fertnstert.2018.11.047","volume":"111","author":"M Cozzolino","year":"2019","unstructured":"Cozzolino M, Vitagliano A, Cecchino GN, Ambrosini G, Garcia-Velasco JA. Corifollitropin alfa for ovarian stimulation in in vitro fertilization: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2019;111:722\u201333.","journal-title":"Fertil Steril"},{"key":"1113_CR21","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/humrep\/deac061","volume":"37","author":"M Fern\u00e1ndez S\u00e1nchez","year":"2022","unstructured":"Fern\u00e1ndez S\u00e1nchez M, Vi\u0161nov\u00e1 H, Larsson P, Yding Andersen C, Filicori M, Blockeel C, Pinborg A, Khalaf Y, Mannaerts B, Rainbow Study Group. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol. Hum Reprod. 2022;37:1161\u201374.","journal-title":"Hum Reprod"},{"key":"1113_CR22","unstructured":"Green-top guideline No. 5: The management of ovarian hyperstimulation syndrome. https:\/\/www.rcog.org.uk\/media\/or1jqxbf\/gtg_5_ohss.pdf (11 Jan 2023 date last accessed)."},{"key":"1113_CR23","doi-asserted-by":"crossref","unstructured":"Boothroyd C, Karia S, Andreadis N, Rombauts L, Johnson N, Chapman M. Australasian CREI Consensus Expert Panel on Trial evidence (ACCEPT) group. Consensus statement on prevention and detection of ovarian hyperstimulation syndrome. Aust N Z J Obstet Gynaecol. 2015;55:523\u201334.","DOI":"10.1111\/ajo.12406"},{"key":"1113_CR24","first-page":"CD012103","volume":"1","author":"S Mourad","year":"2017","unstructured":"Mourad S, Brown J, Farquhar C. Interventions for the prevention of OHSS in ART cycles: an overview of cochrane reviews. Cochrane Database Syst Rev. 2017;1:CD012103.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR25","first-page":"378e070849","volume":"9","author":"M Gates","year":"2022","unstructured":"Gates M, Gates A, Pieper D, Fernandes RM, Tricco AC, Moher D, Brennan SE, Li T, Pollock M, Lunny C, et al. Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement. BMJ. 2022;9:378e070849.","journal-title":"BMJ"},{"key":"1113_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jclinepi.2020.07.005","volume":"127","author":"TF Frandsen","year":"2020","unstructured":"Frandsen TF, Bruun Nielsen MF, Lindhardt CL, Eriksen MB. Using the full PICO model as a search tool for systematic reviews resulted in lower recall for some PICO elements. J Clin Epidemiol. 2020;127:69\u201375.","journal-title":"J Clin Epidemiol"},{"key":"1113_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1741-7015-9-79","volume":"9","author":"T Li","year":"2011","unstructured":"Li T, Puhan MA, Vedula SS, Singh S, Dickersin K. Ad Hoc Network Meta-analysis methods meeting Working Group. Network meta-analysis-highly attractive but more methodological research is needed. BMC Med. 2011;9:79.","journal-title":"BMC Med"},{"key":"1113_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5662\/wjm.v12.i3.92","volume":"12","author":"SI Christofilos","year":"2022","unstructured":"Christofilos SI, Tsikopoulos K, Tsikopoulos A, Kitridis D, Sidiropoulos K, Stoikos PN, Kavarthapu V. Network meta-analyses: methodological prerequisites and clinical usefulness. World J Methodol. 2022;12:92\u20138.","journal-title":"World J Methodol"},{"key":"1113_CR29","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.","journal-title":"BMJ"},{"key":"1113_CR30","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. www.cochrane-handbook.org."},{"key":"1113_CR31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejogrb.2021.02.023","volume":"259","author":"K Tang","year":"2021","unstructured":"Tang K, Wu L, Luo Y, Gong B. In vitro fertilization outcomes in women with polycystic ovary syndrome: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021;259:146\u201352.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1113_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/humrep\/der416","volume":"27","author":"AM Koning","year":"2012","unstructured":"Koning AM, Mutsaerts MA, Kuchenbecker WKH, Broekmans FJ, Land JA, Mol BW, Hoek A. Complications and outcome of assisted reproduction technologies in overweight and obese women. Hum Reprod. 2012;27:457\u201367.","journal-title":"Hum Reprod"},{"key":"1113_CR33","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s10815-015-0600-5","volume":"32","author":"H Tang","year":"2015","unstructured":"Tang H, Yan Y, Wang T, Zhang T, Shi W, Fan R, Yao Y, Zhai S. Effect of follicle-stimulating hormone receptor Asn680Ser polymorphism on the outcomes of controlled ovarian hyperstimulation: an updated meta-analysis of 16 cohort studies. J Assist Reprod Genet. 2015;32:1801\u201310.","journal-title":"J Assist Reprod Genet"},{"key":"1113_CR34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/humrep\/dem254","volume":"23","author":"TH Lee","year":"2008","unstructured":"Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, Yang YS, Lee MS. Serum anti-M\u00fcllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod. 2008;23:160\u20137.","journal-title":"Hum Reprod"},{"key":"1113_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1023\/B:JARG.0000027016.65749.ad","volume":"21","author":"DJ Hendriks","year":"2004","unstructured":"Hendriks DJ, Klinkert ER, Bancsi LF, Looman CW, Habbema JD, te Velde ER, Broekmans FJ. Use of stimulated serum estradiol measurements for the prediction of hyperresponse to ovarian stimulation in in vitro fertilization (IVF). J Assist Reprod Genet. 2004;21:65\u201372.","journal-title":"J Assist Reprod Genet"},{"key":"1113_CR36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.fertnstert.2012.05.042","volume":"98","author":"K Jayaprakasan","year":"2012","unstructured":"Jayaprakasan K, Chan Y, Islam R, Haoula Z, Hopkisson J, Coomarasamy A, Raine-Fenning N. Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. Fertil Steril. 2012;98:657\u201363.","journal-title":"Fertil Steril"},{"key":"1113_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12958-020-00685-x","volume":"19","author":"J Zhao","year":"2021","unstructured":"Zhao J, Yao Z, Hao J, Xu B, Wang Y, Li Y. Association of ABO blood groups with ovarian reserve, and outcomes after assisted reproductive technology: systematic review and meta-analyses. Reprod Biol Endocrinol. 2021;19:20.","journal-title":"Reprod Biol Endocrinol"},{"key":"1113_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/humupd\/dmm034","volume":"14","author":"BC Fauser","year":"2008","unstructured":"Fauser BC, Diedrich K, Evian Annual Reproduction Workshop Group 2007. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update. 2008;14:1\u201314.","journal-title":"Hum Reprod Update"},{"key":"1113_CR39","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.fertnstert.2013.04.024","volume":"100","author":"SL Broer","year":"2013","unstructured":"Broer SL, D\u00f3lleman M, van Disseldorp J, Broeze KA, Opmeer BC, Bossuyt PM, Eijkemans MJ, Mol BW, Broekmans FJ, IPD-EXPORT Study Group. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. Fertil Steril. 2013;100:420\u20139.","journal-title":"Fertil Steril"},{"key":"1113_CR40","first-page":"CD012693","volume":"2","author":"SF Lensen","year":"2018","unstructured":"Lensen SF, Wilkinson J, Leijdekkers JA, La Marca A, Mol BWJ, Marjoribanks J, Torrance H, Broekmans FJ. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF\/ICSI). Cochrane Database Syst Rev. 2018;2:CD012693.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR41","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3109\/00016340903287482","volume":"88","author":"A Kahnberg","year":"2009","unstructured":"Kahnberg A, Enskog A, Br\u00e4nnstr\u00f6m M, Lundin K, Bergh C. Prediction of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization. Acta Obstet Gynecol Scand. 2009;88:1373\u201381.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"1113_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/uog.12566","volume":"43","author":"WP Martins","year":"2014","unstructured":"Martins WP, Vieira CV, Teixeira DM, Barbosa MA, Dassun\u00e7\u00e3o LA, Nastri CO. Ultrasound for monitoring controlled ovarian stimulation: a systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol. 2014;43:25\u201333.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"1113_CR43","first-page":"CD005289","volume":"4","author":"I Kwan","year":"2021","unstructured":"Kwan I, Bhattacharya S, Woolner A. Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database Syst Rev. 2021;4:CD005289.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/humupd\/8.2.129","volume":"8","author":"MJ Pelinck","year":"2002","unstructured":"Pelinck MJ, Hoek A, Simons AH, Heineman MJ. Efficacy of natural cycle IVF: a review of the literature. Hum Reprod Update. 2002;8:129\u201339.","journal-title":"Hum Reprod Update"},{"key":"1113_CR45","first-page":"CD010550","volume":"2013","author":"T Allersma","year":"2013","unstructured":"Allersma T, Farquhar C, Cantineau AE. Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database Syst Rev. 2013;2013:CD010550.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR46","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/humrep\/dew325","volume":"32","author":"D Wei","year":"2017","unstructured":"Wei D, Shi Y, Li J, Wang Z, Zhang L, Sun Y, Zhou H, Xu Y, Wu C, Liu L, et al. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome. Hum Reprod. 2017;32:354\u201361.","journal-title":"Hum Reprod"},{"key":"1113_CR47","first-page":"CD006109","volume":"5","author":"C Farquhar","year":"2017","unstructured":"Farquhar C, Rombauts L, Kremer JA, Lethaby A, Ayeleke RO. Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database Syst Rev. 2017;5:CD006109.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR48","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.fertnstert.2009.09.009","volume":"92","author":"F Zegers-Hochschild","year":"2009","unstructured":"Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K, Sullivan E, Vanderpoel S, International Committee for Monitoring Assisted Reproductive Technology, World Health Organization. International Committee for Monitoring assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology. Fertil Steril. 2009;92:1520\u20134.","journal-title":"Fertil Steril"},{"key":"1113_CR49","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000355980","volume":"76","author":"T Matsaseng","year":"2013","unstructured":"Matsaseng T, Kruger T, Steyn W. Mild ovarian stimulation for in vitro fertilization: are we ready to change? A meta-analysis. Gynecol Obstet Invest. 2013;76:233\u201340.","journal-title":"Gynecol Obstet Invest"},{"key":"1113_CR50","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1080\/09513590.2017.1320385","volume":"33","author":"Y Fan","year":"2017","unstructured":"Fan Y, Zhang X, Hao Z, Ding H, Chen Q, Tian L. Effectiveness of mild ovarian stimulation versus GnRH agonist protocol in women undergoing assisted reproductive technology: a meta-analysis. Gynecol Endocrinol. 2017;33:746\u201356.","journal-title":"Gynecol Endocrinol"},{"key":"1113_CR51","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/humupd\/dmaa035","volume":"27","author":"AK Datta","year":"2021","unstructured":"Datta AK, Maheshwari A, Felix N, Campbell S, Nargund G. Mild versus conventional ovarian stimulation for IVF in poor, normal and hyper-responders: a systematic review and meta-analysis. Hum Reprod Update. 2021;27:229\u201353.","journal-title":"Hum Reprod Update"},{"key":"1113_CR52","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S0015-0282(01)03246-0","volume":"77","author":"S Daya","year":"2002","unstructured":"Daya S. Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertil Steril. 2002;77:711\u20134.","journal-title":"Fertil Steril"},{"key":"1113_CR53","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/humrep\/deg229","volume":"18","author":"M Van Wely","year":"2003","unstructured":"Van Wely M, Bayram N, van der Veen F. Recombinant FSH in alternative doses or versus urinary gonadotrophins for ovulation induction in subfertility associated with polycystic ovary syndrome: a systematic review based on a Cochrane review. Hum Reprod. 2003;18:1143\u20139.","journal-title":"Hum Reprod"},{"key":"1113_CR54","first-page":"CD003973","volume":"1","author":"M Van Wely","year":"2003","unstructured":"Van Wely M, Westergaard LG, Bossuyt PM, Van der Veen F. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2003;1:CD003973.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR55","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/humrep\/dem305","volume":"23","author":"A Coomarasamy","year":"2008","unstructured":"Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod. 2008;23:310\u20135.","journal-title":"Hum Reprod"},{"key":"1113_CR56","first-page":"CD005354","volume":"2011","author":"M Van Wely","year":"2011","unstructured":"Van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al-Inany HG. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011;2011:CD005354.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2165\/00063030-200923010-00004","volume":"23","author":"Z Saz-Parkinson","year":"2009","unstructured":"Saz-Parkinson Z, L\u00f3pez-Cuadrado T, Bouza C, Amate JM. Outcomes of new quality standards of follitropin alfa on ovarian stimulation: meta-analysis of previous studies. BioDrugs. 2009;23:37\u201342.","journal-title":"BioDrugs"},{"key":"1113_CR58","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.rbmo.2016.04.005","volume":"33","author":"G Griesinger","year":"2016","unstructured":"Griesinger G, Boostanfar R, Gordon K, Gates D, McCrary Sisk C, Stegmann BJ. Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis. Reprod Biomed Online. 2016;33:56\u201360.","journal-title":"Reprod Biomed Online"},{"key":"1113_CR59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13048-015-0160-4","volume":"8","author":"S Fensore","year":"2015","unstructured":"Fensore S, Di Marzio M, Tiboni GM. Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis. J Ovarian Res. 2015;8:33.","journal-title":"J Ovarian Res"},{"key":"1113_CR60","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.fertnstert.2012.01.092","volume":"97","author":"MA Mahmoud Youssef","year":"2012","unstructured":"Mahmoud Youssef MA, van Wely M, Aboulfoutouh I, El-Khyat W, van der Veen F, Al-Inany H. Is there a place for corifollitropin alfa in IVF\/ICSI cycles? A systematic review and meta-analysis. Fertil Steril. 2012;97:876\u201385.","journal-title":"Fertil Steril"},{"key":"1113_CR61","doi-asserted-by":"publisher","first-page":"675670","DOI":"10.3389\/fendo.2021.675670","volume":"12","author":"R Orvieto","year":"2021","unstructured":"Orvieto R, Venetis CA, Fatemi HM, D\u2019Hooghe T, Fischer R, Koloda Y, Horton M, Grynberg M, Longobardi S, Esteves SC, Sunkara SK, Li Y, Alviggi C. Optimising follicular development, pituitary suppression, triggering and luteal phase support during assisted reproductive technology: a Delphi consensus. Front Endocrinol (Lausanne). 2021;12:675670.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1113_CR62","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1472-6483(10)61186-8","volume":"12","author":"C Alviggi","year":"2006","unstructured":"Alviggi C, Clarizia R, Mollo A, Ranieri A, De Placido G. Outlook: who needs LH in ovarian stimulation? Reprod Biomed Online. 2006;12:599\u2013607.","journal-title":"Reprod Biomed Online"},{"key":"1113_CR63","first-page":"CD005070","volume":"5","author":"MH Mochtar","year":"2017","unstructured":"Mochtar MH, Danhof NA, Ayeleke RO, Van der Veen F, van Wely M. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF\/ICSI cycles. Cochrane Database Syst Rev. 2017;5:CD005070.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR64","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1210\/jc.2014-4235","volume":"100","author":"S Palomba","year":"2015","unstructured":"Palomba S. Aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab. 2015;100:1742\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"1113_CR65","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/cncr.10908","volume":"95","author":"AU Buzdar","year":"2002","unstructured":"Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002;95:2006\u201316.","journal-title":"Cancer"},{"key":"1113_CR66","first-page":"CD008528","volume":"11","author":"MS Kamath","year":"2017","unstructured":"Kamath MS, Maheshwari A, Bhattacharya S, Lor KY, Gibreel A. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation. Cochrane Database Syst Rev. 2017;11:CD008528.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR67","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00404-012-2672-0","volume":"287","author":"JB Figueiredo","year":"2013","unstructured":"Figueiredo JB, Nastri CO, Vieira AD, Martins WP. Clomiphene combined with gonadotropins and GnRH antagonist versus conventional controlled ovarian hyperstimulation without clomiphene in women undergoing assisted reproductive techniques: systematic review and meta-analysis. Arch Gynecol Obstet. 2013;287:779\u201390.","journal-title":"Arch Gynecol Obstet"},{"key":"1113_CR68","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/uog.17442","volume":"50","author":"TN Bechtejew","year":"2017","unstructured":"Bechtejew TN, Nadai MN, Nastri CO, Martins WP. Clomiphene citrate and letrozole to reduce follicle-stimulating hormone consumption during ovarian stimulation: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2017;50:315\u201323.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"1113_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/er.2008-0030","volume":"30","author":"S Palomba","year":"2009","unstructured":"Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009;30:1\u201350.","journal-title":"Endocr Rev"},{"key":"1113_CR70","first-page":"1","volume":"26","author":"A Unanyan","year":"2022","unstructured":"Unanyan A, Pivazyan L, Krylova E, Eskin A, Zakaryan A, Sarkisova A, Ishchenko A. Effectiveness of inositol, metformin and their combination in women with PCOS undergoing assisted reproduction: systematic review and meta-analysis. Gynecol Endocrinol. 2022;26:1\u201312.","journal-title":"Gynecol Endocrinol"},{"key":"1113_CR71","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejogrb.2022.01.025","volume":"271","author":"R Magzoub","year":"2022","unstructured":"Magzoub R, Kheirelseid EAH, Perks C, Lewis S. Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review. Eur J Obstet Gynecol Reprod Biol. 2022;271:38\u201362.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1113_CR72","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijgo.2015.04.046","volume":"131","author":"X Huang","year":"2015","unstructured":"Huang X, Wang P, Tal R, Lv F, Li Y, Zhang X. A systematic review and meta- analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures. Int J Gynaecol Obstet. 2015;131:111\u20136.","journal-title":"Int J Gynaecol Obstet"},{"key":"1113_CR73","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1093\/humrep\/dei501","volume":"21","author":"MF Costello","year":"2006","unstructured":"Costello MF, Chapman M, Conway U. A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome. Hum Reprod. 2006;21:1387\u201399.","journal-title":"Hum Reprod"},{"key":"1113_CR74","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/humupd\/dmm026","volume":"13","author":"E Moll","year":"2007","unstructured":"Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update. 2007;13:527\u201337.","journal-title":"Hum Reprod Update"},{"key":"1113_CR75","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/1471-0528.12070","volume":"120","author":"S Palomba","year":"2013","unstructured":"Palomba S, Falbo A, La Sala GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilization and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG. 2013;120:267\u201376.","journal-title":"BJOG"},{"key":"1113_CR76","doi-asserted-by":"publisher","first-page":"e2011995","DOI":"10.1001\/jamanetworkopen.2020.11995","volume":"3","author":"Y Wu","year":"2020","unstructured":"Wu Y, Tu M, Huang Y, Liu Y, Zhang D. Association of metformin with pregnancy outcomes in women with polycystic ovarian syndrome undergoing in vitro fertilization: a systematic review and meta-analysis. JAMA Netw Open. 2020;3:e2011995.","journal-title":"JAMA Netw Open"},{"key":"1113_CR77","first-page":"CD006105","volume":"12","author":"LO Tso","year":"2020","unstructured":"Tso LO, Costello MF, Albuquerque LET, Andriolo RB, Macedo CR. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2020;12:CD006105.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR78","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1210\/er.2018-00084","volume":"39","author":"J Cipolla-Neto","year":"2018","unstructured":"Cipolla-Neto J, Amaral FGD. Melatonin as a hormone: new physiological and clinical insights. Endocr Rev. 2018;39:990\u20131028.","journal-title":"Endocr Rev"},{"key":"1113_CR79","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.fertnstert.2013.09.036","volume":"101","author":"LM Seko","year":"2014","unstructured":"Seko LM, Moroni RM, Leitao VM, Teixeira DM, Nastri CO, Martins WP. Melatonin supplementation during controlled ovarian stimulation for women undergoing assisted reproductive technology: systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2014;101:154\u201361.","journal-title":"Fertil Steril"},{"key":"1113_CR80","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/humupd\/8.3.291","volume":"8","author":"A Delvigne","year":"2002","unstructured":"Delvigne A, Rozenberg S. A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. Hum Reprod Update. 2002;8:291\u20136.","journal-title":"Hum Reprod Update"},{"key":"1113_CR81","first-page":"CD002811","volume":"5","author":"A D\u2019Angelo","year":"2017","unstructured":"D\u2019Angelo A, Amso NN, Hassan R. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2017;5:CD002811.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR82","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.fertnstert.2010.06.068","volume":"95","author":"D Bodri","year":"2011","unstructured":"Bodri D, Sunkara SK, Coomarasamy A. Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis. Fertil Steril. 2011;95:164\u20139.","journal-title":"Fertil Steril"},{"key":"1113_CR83","first-page":"4CD001750","volume":"29","author":"HG Al-Inany","year":"2016","unstructured":"Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;29:4CD001750.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR84","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/humupd\/dmx017","volume":"23","author":"CB Lambalk","year":"2017","unstructured":"Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, van der Veen F, van Wely M. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23:560\u201379.","journal-title":"Hum Reprod Update"},{"key":"1113_CR85","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3109\/09513590.2010.526667","volume":"27","author":"F Mancini","year":"2011","unstructured":"Mancini F, Tur R, Martinez F, Coroleu B, Rodr\u00edguez I, Barri PN. Gonadotrophin-releasing hormone-antagonists vs long agonist in in-vitro fertilization patients with polycystic ovary syndrome: a meta-analysis. Gynecol Endocrinol. 2011;27:150\u20135.","journal-title":"Gynecol Endocrinol"},{"key":"1113_CR86","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.rbmo.2011.09.017","volume":"24","author":"J Pundir","year":"2012","unstructured":"Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reprod Biomed Online. 2012;24:6\u201322.","journal-title":"Reprod Biomed Online"},{"key":"1113_CR87","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/09513590.2012.736561","volume":"29","author":"J Xiao","year":"2013","unstructured":"Xiao J, Chen S, Zhang C, Chang S. Effectiveness of GnRH antagonist in the treatment of patients with polycystic ovary syndrome undergoing IVF: a systematic review and meta-analysis. Gynecol Endocrinol. 2013;29:187\u201391.","journal-title":"Gynecol Endocrinol"},{"key":"1113_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091796","volume":"9","author":"H Lin","year":"2014","unstructured":"Lin H, Li Y, Li L, Wang W, Yang D, Zhang Q. Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs. PLoS One. 2014;9: e91796.","journal-title":"PLoS One"},{"key":"1113_CR89","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1038\/s41598-022-08400-z","volume":"12","author":"S Kadoura","year":"2022","unstructured":"Kadoura S, Alhalabi M, Nattouf AH. Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF\/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis. Sci Rep. 2022;12:4456.","journal-title":"Sci Rep"},{"key":"1113_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106854","volume":"9","author":"JS Xiao","year":"2014","unstructured":"Xiao JS, Su CM, Zeng XT. Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis. PLoS One. 2014;9: e106854.","journal-title":"PLoS One"},{"key":"1113_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175985","volume":"12","author":"R Wang","year":"2017","unstructured":"Wang R, Lin S, Wang Y, Qian W, Zhou L. Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: a systematic review and meta-analysis. PLoS ONE. 2017;12:e0175985.","journal-title":"PLoS One"},{"key":"1113_CR92","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/humrep\/dex367","volume":"33","author":"S Yu","year":"2018","unstructured":"Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, Quan X, Lyu Q, Kuang Y, Ai A. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF\/ICSI cycles. Hum Reprod. 2018;33:229\u201337.","journal-title":"Hum Reprod"},{"key":"1113_CR93","doi-asserted-by":"publisher","first-page":"702558","DOI":"10.3389\/fendo.2021.702558","volume":"12","author":"S Guan","year":"2021","unstructured":"Guan S, Feng Y, Huang Y, Huang J. Progestin-primed ovarian stimulation protocol for patients in assisted reproductive technology: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2021;12:702558.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1113_CR94","first-page":"CD003719","volume":"4","author":"MA Youssef","year":"2016","unstructured":"Youssef MA, Abou-Setta AM, Lam WS. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst Rev. 2016;4:CD003719.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR95","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/humupd\/dmi045","volume":"12","author":"G Griesinger","year":"2006","unstructured":"Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2006;12:159\u201368.","journal-title":"Hum Reprod Update"},{"key":"1113_CR96","first-page":"CD008046","volume":"4","author":"MA Youssef","year":"2014","unstructured":"Youssef MA, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, Aboulfoutouh I, van Wely M. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev. 2014;4:CD008046.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR97","first-page":"1507","volume":"83","author":"The European Recombinant Human LH Study Group","year":"1998","unstructured":"The European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab. 1998;83:1507\u201314.","journal-title":"J Clin Endocrinol Metab"},{"key":"1113_CR98","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.fertnstert.2006.03.017","volume":"86","author":"K Oktay","year":"2006","unstructured":"Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril. 2006;86:70\u201380.","journal-title":"Fertil Steril"},{"key":"1113_CR99","first-page":"CD011184","volume":"2","author":"T Zaat","year":"2021","unstructured":"Zaat T, Zagers M, Mol F, Goddijn M, van Wely M, Mastenbroek S. Fresh versus frozen embryo transfers in assisted reproduction. Cochrane Database Syst Rev. 2021;2:CD011184.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR100","first-page":"CD002806","volume":"3","author":"A D\u2019Angelo","year":"2007","unstructured":"D\u2019Angelo A, Amso NN. Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2007;3:CD002806.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR101","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.bpobgyn.2018.06.004","volume":"53","author":"ML Walls","year":"2018","unstructured":"Walls ML, Hart RJ. In vitro maturation. Best Pract Res Clin Obstet Gynaecol. 2018;53:60\u201372.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"1113_CR102","first-page":"CD006606","volume":"11","author":"CS Siristatidis","year":"2018","unstructured":"Siristatidis CS, Maheshwari A, Vaidakis D, Bhattacharya S. In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database Syst Rev. 2018;11:CD006606.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR103","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/87895","volume":"7","author":"S Basu","year":"2001","unstructured":"Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor\/vascular endothelial growth factor. Nat Med. 2001;7:569\u201374.","journal-title":"Nat Med"},{"key":"1113_CR104","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/humupd\/dmq006","volume":"16","author":"MA Youssef","year":"2010","unstructured":"Youssef MA, van Wely M, Hassan MA, Al-Inany HG, Mochtar M, Khattab S, van der Veen F. Can dopamine agonists reduce the incidence and severity of OHSS in IVF\/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update. 2010;16:459\u201366.","journal-title":"Hum Reprod Update"},{"key":"1113_CR105","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.fertnstert.2013.11.005","volume":"101","author":"VM Leitao","year":"2014","unstructured":"Leitao VM, Moroni RM, Seko LM, Nastri CO, Martins WP. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2014;101:664\u201375.","journal-title":"Fertil Steril"},{"key":"1113_CR106","first-page":"CD008605","volume":"4","author":"H Tang","year":"2021","unstructured":"Tang H, Mourad SM, Wang A, Zhai SD, Hart RJ. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2021;4:CD008605.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR107","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1021\/jf8006568","volume":"56","author":"O Benavente-Garc\u00eda","year":"2008","unstructured":"Benavente-Garc\u00eda O, Castillo J. Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem. 2008;56:6185\u2013205.","journal-title":"J Agric Food Chem"},{"key":"1113_CR108","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000286379","volume":"70","author":"BC Jee","year":"2010","unstructured":"Jee BC, Suh CS, Kim YB, Kim SH, Choi YM, Kim JG, Moon SY. Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome: a systematic review and meta-analysis. Gynecol Obstet Invest. 2010;70:47\u201354.","journal-title":"Gynecol Obstet Invest"},{"key":"1113_CR109","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.fertnstert.2010.05.026","volume":"95","author":"CA Venetis","year":"2011","unstructured":"Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Papadimas I, Tarlatzis BC. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95:188\u201396.","journal-title":"Fertil Steril"},{"key":"1113_CR110","first-page":"711","volume":"40","author":"RS Morris","year":"1995","unstructured":"Morris RS, Miller C, Jacobs L, Miller K. Conservative management of ovarian hyperstimulation syndrome. J Reprod Med. 1995;40:711\u20134.","journal-title":"J Reprod Med"},{"key":"1113_CR111","first-page":"CD001302","volume":"2016","author":"MA Youssef","year":"2016","unstructured":"Youssef MA, Mourad S. Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2016;2016:CD001302.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR112","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jri.2018.03.003","volume":"127","author":"N L\u00e9d\u00e9e","year":"2018","unstructured":"L\u00e9d\u00e9e\u2002N, Prat-Ellenberg\u2002L, Chevrier\u2002L, Petitbarat\u2002M, Simon\u2002C, Irani\u2002EE, et al. Impact of prednisone in patients with repeated embryo implantation failures: beneficial or deleterious? J Reprod Immunol. 2018;127:11\u20135.","journal-title":"J Reprod Immunol"},{"key":"1113_CR113","first-page":"CD004752","volume":"3","author":"T Kalampokas","year":"2017","unstructured":"Kalampokas T, Pandian Z, Keay SD, Bhattacharya S. Glucocorticoid supplementation during ovarian stimulation for IVF or ICSI. Cochrane Database Syst Rev. 2017;3:CD004752.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR114","first-page":"CD005996","volume":"6","author":"CM Boomsma","year":"2022","unstructured":"Boomsma CM, Kamath MS, Keay SD, Macklon NS. Peri-implantation glucocorticoid administration for assisted reproductive technology cycles. Cochrane Database Syst Rev. 2022;6:CD005996.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR115","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S1472-6483(10)61435-6","volume":"13","author":"A Tavaniotou","year":"2006","unstructured":"Tavaniotou A, Devroey P. Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles. Reprod Biomed Online. 2006;13:326\u201330.","journal-title":"Reprod Biomed Online"},{"key":"1113_CR116","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12958-021-00696-2","volume":"19","author":"G Shoham","year":"2021","unstructured":"Shoham G, Leong M, Weissman A. A 10-year follow-up on the practice of luteal phase support using worldwide web-based surveys. Reprod Biol Endocrinol. 2021;19:15.","journal-title":"Reprod Biol Endocrinol"},{"key":"1113_CR117","first-page":"CD009154","volume":"7","author":"M Van der Linden","year":"2015","unstructured":"Van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015;7:CD009154.","journal-title":"Cochrane Database Syst Rev"},{"key":"1113_CR118","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.repbio.2020.07.009","volume":"20","author":"I Bar Hava","year":"2020","unstructured":"Bar Hava I, Yafee H, Omer Y, Humaidan P, Ganer Herman H. GnRHa for trigger and luteal phase support in natural cycle frozen embryo transfer - A proof of concept study. Reprod Biol. 2020;20:282\u20137.","journal-title":"Reprod Biol"},{"key":"1113_CR119","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.fertnstert.2016.04.004","volume":"106","author":"I Bar-Hava","year":"2016","unstructured":"Bar-Hava I, Mizrachi Y, Karfunkel-Doron D, Omer Y, Sheena L, Carmon N, Ben-David G. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders. Fertil Steril. 2016;106:330\u20133.","journal-title":"Fertil Steril"},{"key":"1113_CR120","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000501204","volume":"85","author":"X Ma","year":"2020","unstructured":"Ma X, Du W, Hu J, Yang Y, Zhang X. Effect of gonadotrophin-releasing hormone agonist addition for luteal support on pregnancy outcome in vitro fertilization\/intracytoplasmic sperm injection cycles: a meta-analysis based on randomized controlled trials. Gynecol Obstet Invest. 2020;85:13\u201325.","journal-title":"Gynecol Obstet Invest"},{"key":"1113_CR121","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1152\/ajprenal.00143.2009","volume":"298","author":"WH Beierwaltes","year":"2010","unstructured":"Beierwaltes WH. The role of calcium in the regulation of renin secretion. Am J Physiol Renal Physiol. 2010;298:F1\u201311.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1113_CR122","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00404-009-1135-8","volume":"281","author":"D Herr","year":"2010","unstructured":"Herr D, Duncan WC, Hack G, Konrad R, Kreienberg R, Wulff C. Regulated expression of the renin-angiotensin-system in human granulosa lutein cells: angiotensin II increases VEGF expression but its synthesis is reduced by hCG. Arch Gynecol Obstet. 2010;281:409\u201316.","journal-title":"Arch Gynecol Obstet"},{"key":"1113_CR123","doi-asserted-by":"crossref","unstructured":"Aakvaag A, Gj\u00f8nnaess H. Hormonal response to electrocautery of the ovary in patients with polycystic ovarian disease. BJOG. 1985;92:1258\u201364.","DOI":"10.1111\/j.1471-0528.1985.tb04872.x"},{"key":"1113_CR124","doi-asserted-by":"crossref","unstructured":"Balen A, Tan SL, Jacobs H. Hypersecretion of luteinising hormone. A significant cause of infertility and miscarriage. BJOG. 1993;100:1082\u20139.","DOI":"10.1111\/j.1471-0528.1993.tb15170.x"},{"key":"1113_CR125","doi-asserted-by":"crossref","unstructured":"Bordewijk EM, Ng KYB, Rakic L, Mol BWJ, Brown J, Crawford TJ, van Wely M. Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2020;2:CD001122.","DOI":"10.1002\/14651858.CD001122.pub5"},{"key":"1113_CR126","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12:103\u201311.","journal-title":"Intern Emerg Med"},{"key":"1113_CR127","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s10815-022-02503-2","volume":"39","author":"A Marino","year":"2022","unstructured":"Marino A, Gullo S, Sammartano F, Volpes A, Allegra A. Algorithm-based individualization methodology of the starting gonadotropin dose in IVF\/ICSI and the freeze-all strategy prevent OHSS equally in normal responders: a systematic review and network meta-analysis of the evidence. J Assist Reprod Genet. 2022;39:1583\u2013601.","journal-title":"J Assist Reprod Genet"},{"key":"1113_CR128","doi-asserted-by":"publisher","first-page":"808517","DOI":"10.3389\/fendo.2022.808517","volume":"13","author":"D Wu","year":"2022","unstructured":"Wu D, Shi H, Yu Y, Yu T, Zhai J. Comparison of the effectiveness of various medicines in the prevention of ovarian hyperstimulation syndrome: a network meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:808517.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1113_CR129","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.rbmo.2021.01.023","volume":"42","author":"O Ishihara","year":"2021","unstructured":"Ishihara O, Arce JC, Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in japanese IVF\/ICSI patients: a randomized controlled trial. Reprod Biomed Online. 2021;42:909\u201318.","journal-title":"Reprod Biomed Online"},{"key":"1113_CR130","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","volume":"107","author":"A Nyboe Andersen","year":"2017","unstructured":"Nyboe Andersen A, Nelson SM, Fauser BC, Garc\u00eda-Velasco JA, Klein BM, Arce JC, ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017;107:387\u2013396e4.","journal-title":"Fertil Steril"},{"key":"1113_CR131","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1210\/jc.2015-2332","volume":"100","author":"A Abbara","year":"2015","unstructured":"Abbara A, Jayasena CN, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Nijher GM, Comninos AN, Peters D, Buckley A, Ratnasabapathy R, Prague JK, Salim R, Lavery SA, Bloom SR, Szigeti M, Ashby DA, Trew GH, Dhillo WS. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. J Clin Endocrinol Metab. 2015;100:3322\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"1113_CR132","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s12325-020-01612-7","volume":"38","author":"R Yang","year":"2021","unstructured":"Yang R, Guan Y, Perrot V, Ma J, Li R. Comparison of the long-acting GnRH agonist follicular protocol with the GnRH antagonist protocol in women undergoing in vitro fertilization: a systematic review and meta-analysis. Adv Ther. 2021;38:2027\u201337.","journal-title":"Adv Ther"},{"key":"1113_CR133","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12978-020-01042-2","volume":"17","author":"J Zhao","year":"2020","unstructured":"Zhao J, Xu B, Huang X, Yan Y, Li Y. Whether letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis. Reprod Health. 2020;17:181.","journal-title":"Reprod Health"}],"container-title":["Reproductive Biology and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-023-01113-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12958-023-01113-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-023-01113-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T07:04:19Z","timestamp":1689923059000},"score":1,"resource":{"primary":{"URL":"https:\/\/rbej.biomedcentral.com\/articles\/10.1186\/s12958-023-01113-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":133,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1113"],"URL":"https:\/\/doi.org\/10.1186\/s12958-023-01113-6","relation":{},"ISSN":["1477-7827"],"issn-type":[{"value":"1477-7827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"15 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}